Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125844 | 0.83 | NPSR1 (0.53) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL28346960 | 0.82 | NPSR1 (0.50) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL14969612 | 0.80 | NPC1 (0.54) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL16803423 | 0.80 | NPSR1 (0.50) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL5618885 | 0.78 | FFAR1 (0.55) | NPSR1VCPFFAR1FFAR4RAB9A | |
| SCHEMBL2124714 | 0.77 | NPSR1 (0.49) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL2123773 | 0.76 | NPSR1 (0.55) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL16803426 | 0.75 | NPSR1 (0.53) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL16803392 | 0.74 | NPSR1 (0.44) | NPSR1VCPFFAR1FFAR4NPC1 | |
| SCHEMBL28481224 | 0.73 | CES2 (0.49) | NPSR1FFAR1FFAR4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8741837-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | NPSR1 3203/4885VCP 204/4885FFAR1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.